GLMD Key Statistics, Chart & Performance
The current stock price of GLMD is 1.21 USD. In the past month the price increased by 0.41%. In the past year, price decreased by -59.26%.
GLMD Latest News, Press Relases and Analysis
GLMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About GLMD
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Company Info
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 5
Phone: 97236938448
GALMED PHARMACEUTICALS LTD / GLMD FAQ
What does GLMD do?
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Can you provide the latest stock price for GALMED PHARMACEUTICALS LTD?
The current stock price of GLMD is 1.21 USD. The price increased by 8.04% in the last trading session.
Does GALMED PHARMACEUTICALS LTD pay dividends?
GLMD does not pay a dividend.
How is the ChartMill rating for GALMED PHARMACEUTICALS LTD?
GLMD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists GLMD stock?
GLMD stock is listed on the Nasdaq exchange.
Should I buy GLMD stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GLMD.
Can you provide the market cap for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 8.64M USD. This makes GLMD a Nano Cap stock.
GLMD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GLMD. When comparing the yearly performance of all stocks, GLMD is a bad performer in the overall market: 92.92% of all stocks are doing better.
GLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. GLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GLMD Financial Highlights
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 85.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | -45.52% | ||
| Debt/Equity | 0 |